AstraZeneca PLC Director/PDMR Shareholding (6358A)
March 27 2017 - 9:00AM
UK Regulatory
TIDMAZN
RNS Number : 6358A
AstraZeneca PLC
27 March 2017
27 March 2017 15:00 BST
TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITIES
AstraZeneca PLC (the Company) announces that, on 24 March 2017,
certain Persons Discharging Managerial Responsibilities of the
Company (PDMRs) were each granted awards of the Company's ordinary
shares of $0.25 each (Ordinary Shares) or of American Depositary
Shares (ADSs) under the terms of the AstraZeneca Deferred Bonus
Plan (AZDBP) and the AstraZeneca Performance Share Plan (AZPSP), as
detailed in the table below. Two ADSs are equivalent to one
Ordinary Share.
PDMR Ordinary ADSs awarded Ordinary ADSs awarded Award
Shares under Shares under price
awarded the AZDBP awarded the AZPSP per Ordinary
under under Share
the AZDBP the AZPSP / per
ADS
-------------- ----------- ------------- ----------- ------------- --------------
Pascal
Soriot 7,968 125,009 GBP48.80
-------------- ----------- ------------- ----------- ------------- --------------
Marc Dunoyer 4,262 59,439 GBP48.80
-------------- ----------- ------------- ----------- ------------- --------------
Sean Bohen 3,452 97,507 $30.88
-------------- ----------- ------------- ----------- ------------- --------------
Mark Mallon 2,503 82,190 $30.88
-------------- ----------- ------------- ----------- ------------- --------------
The AZDBP award represents the portion of each PDMR's annual
bonus for 2016 that they are required to defer into shares. The
Ordinary Shares and ADSs awarded under the AZDBP are subject to a
three-year holding period (24 March 2017 to 23 March 2020).
The AZPSP award is subject to a combination of performance
measures focused on scientific, commercial and financial
performance assessed over a three-year performance period (1
January 2017 to 31 December 2019). The AZPSP award will vest on the
third anniversary of the date of grant, other than the awards
granted to the Executive Directors, Mr Soriot and Mr Dunoyer, which
will be subject to a further two-year holding period before
vesting.
Details of the performance measures attached to the AZPSP award
can be found in the Directors' Remuneration Report within the
AstraZeneca Annual Report and Form 20-F Information 2016, which is
available on the Company's website at
www.astrazeneca.com/annualreport2016.
The Company also announces that, on 24 March 2017, Mr Bohen was
granted an award of 48,753 ADSs under the terms of the AstraZeneca
Restricted Share Plan (AZRSP) at an award price of $30.88 per ADS.
The ADSs awarded under the AZRSP are subject to continued
employment and will vest on the third anniversary of the date of
grant.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three main therapy areas - Oncology, Cardiovascular & Metabolic
Diseases and Respiratory. The Company also is selectively active in
the areas of Autoimmunity, Neuroscience and Infection. AstraZeneca
operates in over 100 countries and its innovative medicines are
used by millions of patients worldwide. For more information,
please visit www.astrazeneca.com and follow us on Twitter
@AstraZeneca.
Media Enquiries
Esra Erkal-Paler UK/Global +44 203 749 5638
Vanessa Rhodes UK/Global +44 203 749 5736
Karen Birmingham UK/Global +44 203 749 5634
Rob Skelding UK/Global +44 203 749 5821
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677
Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Craig Marks Finance, Fixed Income, M&A +44 7881 615 764
Henry Wheeler Oncology +44 203 749 5797
Mitchell Chan Oncology +1 240 477 3771
Lindsey Trickett Cardiovascular & Metabolic Diseases +1 240 543 7970
Nick Stone Respiratory +44 203 749 5716
Christer Gruvris Autoimmunity, Neuroscience & Infection +44 203 749 5711
US toll free +1 866 381 7277
Adrian Kemp
Company Secretary, AstraZeneca PLC
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHUBVURBRAOUAR
(END) Dow Jones Newswires
March 27, 2017 10:00 ET (14:00 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024